A detailed history of Zurcher Kantonalbank (Zurich Cantonalbank) transactions in Wave Life Sciences Ltd. stock. As of the latest transaction made, Zurcher Kantonalbank (Zurich Cantonalbank) holds 33,491 shares of WVE stock, worth $449,114. This represents 0.0% of its overall portfolio holdings.

Number of Shares
33,491
Previous 33,491 -0.0%
Holding current value
$449,114
Previous $274,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Jul 29, 2024

BUY
$4.38 - $6.48 $62,944 - $93,124
14,371 Added 75.16%
33,491 $167,000
Q1 2024

Apr 25, 2024

SELL
$3.54 - $6.84 $46,480 - $89,809
-13,130 Reduced 40.71%
19,120 $117,000
Q4 2023

Jan 30, 2024

BUY
$4.16 - $6.87 $125,840 - $207,817
30,250 Added 1512.5%
32,250 $162,000
Q3 2023

Oct 25, 2023

SELL
$3.56 - $5.75 $2,360 - $3,812
-663 Reduced 24.9%
2,000 $11,000
Q2 2023

Aug 07, 2023

SELL
$3.51 - $4.69 $1,856 - $2,481
-529 Reduced 16.57%
2,663 $9,000
Q1 2023

May 08, 2023

BUY
$3.58 - $6.3 $11,427 - $20,109
3,192 New
3,192 $13,000
Q2 2021

Jul 30, 2021

SELL
$5.65 - $7.47 $5,248 - $6,939
-929 Closed
0 $0
Q3 2020

Nov 06, 2020

SELL
$8.49 - $19.54 $1,307 - $3,009
-154 Reduced 14.22%
929 $8,000
Q4 2019

Jan 21, 2020

SELL
$7.99 - $37.6 $3,995 - $18,800
-500 Reduced 31.59%
1,083 $9,000
Q2 2019

Jul 30, 2019

SELL
$22.93 - $42.84 $38,545 - $72,014
-1,681 Reduced 51.5%
1,583 $41,000
Q4 2018

Jan 25, 2019

SELL
$37.1 - $50.11 $11,130 - $15,033
-300 Reduced 8.42%
3,264 $137,000
Q3 2018

Nov 09, 2018

BUY
$36.35 - $55.2 $20,501 - $31,132
564 Added 18.8%
3,564 $178,000
Q1 2018

May 03, 2018

BUY
$32.45 - $54.7 $97,350 - $164,100
3,000 New
3,000 $120,000

Others Institutions Holding WVE

About Wave Life Sciences Ltd.


  • Ticker WVE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 86,820,096
  • Market Cap $1.16B
  • Description
  • Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. It is developing oligonucleotides target ribonucleic acid to reduce the expression of disease-promoting proteins or restore the production of functional pr...
More about WVE
Track This Portfolio

Track Zurcher Kantonalbank (Zurich Cantonalbank) Portfolio

Follow Zurcher Kantonalbank (Zurich Cantonalbank) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.